2.16
전일 마감가:
$2.29
열려 있는:
$2.21
하루 거래량:
70,216
Relative Volume:
1.33
시가총액:
$24.16M
수익:
-
순이익/손실:
$-18.92M
주가수익비율:
-1.2324
EPS:
-1.7527
순현금흐름:
$-16.86M
1주 성능:
-14.62%
1개월 성능:
-22.02%
6개월 성능:
-46.40%
1년 성능:
-42.40%
Lantern Pharma Inc Stock (LTRN) Company Profile
명칭
Lantern Pharma Inc
전화
972-277-1136
주소
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
LTRN
Lantern Pharma Inc
|
2.16 | 25.61M | 0 | -18.92M | -16.86M | -1.7527 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-10-07 | 개시 | H.C. Wainwright | Buy |
Lantern Pharma Inc 주식(LTRN)의 최신 뉴스
LTRN: AI-driven drug development yields rapid clinical progress, FDA designations, and new monetization paths - TradingView
Lantern Pharma (LTRN) to Release Earnings on Thursday - Defense World
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET - Quantisnow
Lantern Pharma (LTRN) Stock Forecast and Price Target 2026 $LTRN - MarketBeat
Lake Street Initiates Coverage of Lantern Pharma (LTRN) with Buy Recommendation - MSN
Lantern Pharma (LTRN) Stock Analysis Report | Financials & Insights - Benzinga Japan
Institution Moves: What are Lantern Pharma Incs recent SEC filings showing2025 Institutional Moves & Technical Buy Zone Confirmation - baoquankhu1.vn
What are Lantern Pharma Inc.’s recent SEC filings showingJuly 2025 Review & High Accuracy Trade Alerts - mfd.ru
LTRN Should I Buy - Intellectia AI
Lantern Pharma (LTRN) to Release Quarterly Earnings on Thursday - Defense World
LTRN Technical Analysis & ETF Price Forecast - Intellectia AI
Bull Run: What is Lantern Pharma Incs P E ratio telling usWeekly Market Summary & Real-Time Buy Zone Alerts - baoquankhu1.vn
LTRN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bios group controls 8.58% of Lantern Pharma (LTRN) common stock - Stock Titan
LTRN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition - Bitget
Aug Gainers: Can Lantern Pharma Inc. stock sustain institutional interestMarket Trend Report & Weekly High Potential Stock Alerts - mfd.ru
Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026 - Business Wire
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Asheville Citizen Times
Growth Report: How much upside does GWRE haveMarket Sentiment Report & Daily Entry Point Alerts - baoquankhu1.vn
Patterns Watch: Is Lantern Pharma Inc stock undervalued right nowJuly 2025 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
RedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26 - Corpus Christi Caller-Times
Lantern Pharma to Set Up AI Center of Excellence in Bengaluru to Scale RADR Platform - Digital Health News
FDA grants orphan drug designation to Lantern Pharma’s LP-284 for sarcomas - Investing.com Nigeria
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas - PharmiWeb.com
Lantern Pharma (LTRN) Secures Orphan Drug Designation for LP-284 - GuruFocus
Lantern Pharma Establishes New AI Centre Of Excellence, Agentic Labs Hub In Bengaluru - Voice Of HealthCare
Lantern Pharma Expands Global AI Footprint with Bengaluru Center of Excellence - eHealth Magazine
Critical Comparison: Lantern Pharma (NASDAQ:LTRN) versus Praxis Precision Medicines (NASDAQ:PRAX) - Defense World
FDA Grants Orphan Drug Status to Lantern Pharma's Treatment for Sarcoma (LTRN) - GuruFocus
Lantern Pharma launches AI Center of Excellence in Bengaluru to scale precision drug discovery globally - Indian Pharma Post
Recap Report: Whats the outlook for Lantern Pharma Incs sectorQuarterly Risk Review & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Lantern Pharma establishes AI Centre of Excellence and Advanced Agentic Labs in Bengaluru - BioSpectrum India
History Review: Is Lantern Pharma Inc stock a hidden gemGap Up & Trade Opportunity Analysis Reports - baoquankhu1.vn
Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RAD - PharmiWeb.com
Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies - 01net
Lantern Pharma IncEstablishes Ai Center Of Excellence In Bengaluru - TradingView — Track All Markets
Is Lantern Pharma Inc. stock a contrarian buyJuly 2025 Highlights & AI Forecasted Stock Moves - Улправда
Why Lantern Pharma Inc. stock attracts global investorsEarnings Date Calendar & Top Analyst Picks Available for Free - Улправда
Lantern Pharma (NASDAQ:LTRN) Stock Price Up 6.2% – What’s Next? - Defense World
What analysts say about Lantern Pharma Inc stockMarket Capitalization Trends & Superior Capital Growth - earlytimes.in
Lantern Pharma Inc Stock Analysis and ForecastMACD Histogram Signals & Fast Profit Trading Strategies - earlytimes.in
Is Lantern Pharma Inc a good long term investmentResistance Breakout Alerts & Learn to Trade with Real-Time Feedback - earlytimes.in
Sentiment Recap: Is Lantern Pharma Inc. stock a safe buy before earningsWeekly Profit Summary & Free Expert Approved Momentum Trade Ideas - moha.gov.vn
What Wall Street predicts for Lantern Pharma Inc. stock priceJuly 2025 Update & Verified Entry Point Signals - Улправда
Lantern Pharma’s AI Bet Needs 2026 Trial Wins - Finimize
What momentum indicators show for Lantern Pharma Inc. stockEarnings Miss & AI Optimized Trade Strategies - DonanımHaber
Why Lantern Pharma Inc. stock remains resilientNew Guidance & Target Return Focused Stock Picks - Улправда
Lantern Pharma Inc (LTRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Lantern Pharma Inc 주식 (LTRN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kreis Leslie W. | 10% Owner |
Jun 13 '25 |
Sale |
3.09 |
40,000 |
123,600 |
49,957 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Kreis Leslie W. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Kreis Leslie W. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Kreis Leslie W. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Fletcher Aaron G.L. | 10% Owner |
May 27 '25 |
Sale |
3.05 |
21,037 |
64,163 |
56,467 |
| Fletcher Aaron G.L. | 10% Owner |
May 29 '25 |
Sale |
3.03 |
20,200 |
61,206 |
54,792 |
| Fletcher Aaron G.L. | 10% Owner |
May 28 '25 |
Sale |
2.87 |
15,000 |
43,050 |
55,753 |
자본화:
|
볼륨(24시간):